J6M-MC-JSGD: A Phase 2, Randomized, Open-Label Dose Optimization and Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Tersolisib (LY4064809) Combined with a CDK4/6 Inhibitor and Endocrine Therapy in Adults with HR+, HER2- Advanced Breast Cancer with a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2)

Neoplasm Metastasis, Breast Neoplasms

Part 1: Overall Response Rate (ORR): Percentage of Participants with Confirmed Complete Response (CR) or Partial Response (PR) [Time Frame: Baseline through disease progression or death (Estimated up to 5 years)] As determined by the investigator based on Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1, Part 2: Progression-Free Survival [Time Frame: Baseline to objective progression or death due to any cause (Estimated up to 5 years)] Investigator-assessed

No related papers found yet.

Papers published before 2002-11-01 may not appear yet. Historical indexing is in progress.